A retrospective non-interventional study evaluating retention rate of Everolimus as add-on epilepsy therapy in adult patients with tuberose sclerosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00020248

Enrollment

Registered

2019-12-23

Start date

2020-01-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Q85.1

Interventions

Group 1: The effectiveness and the safety profile of everolimus in adult patients with tuberous sclerosis, epilepsy and treatment with everolimus between 01/01/1999 and 04/30/2019 will be retrospectiv

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Diagnosis epilepsy • at least 1 epileptic seizure in the year before the onset of everolimus • Clinically and / or genetically confirmed tuberous sclerosis • Treatment with everolimus between 01.01.1999 and 30.04.2019 • start treatment with everolimus in adulthood (18 years or older)

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

Measure	Time frame
Retention rate (%) of everolimus after 6 months	—

Secondary

Measure	Time frame
Change in the seizure situation after the onset of everolimus, Responder rate (proportion of patients whose seizure frequency has improved by 50% or more), Seizure rate (rate of patients seizure-free after starting everolimus), Seizure situation in the year before Everolimus begins, Seizure situation in the year after beginning of everolimus, Side effects rate Reasons for discontinuation of everolimus	—

Measure

Time frame

Change in the seizure situation after the onset of everolimus, Responder rate (proportion of patients whose seizure frequency has improved by 50% or more), Seizure rate (rate of patients seizure-free after starting everolimus), Seizure situation in the year before Everolimus begins, Seizure situation in the year after beginning of everolimus, Side effects rate Reasons for discontinuation of everolimus

—

Countries

Germany

Contacts

Public ContactTassanai Intravooth

Epilepsiezentrum Kork

tintravooth@epilepsiezentrum.de00497851842272

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026